Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 122 entries
Sorted by: Best Match Show Resources per page
Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia.

Clinical pharmacology and therapeutics

Hee Nam Y, Brensinger CM, Bilker WB, Flory JH, Leonard CE, Hennessy S.
PMID: 34312836
Clin Pharmacol Ther. 2021 Jul 27; doi: 10.1002/cpt.2377. Epub 2021 Jul 27.

Serious hypoglycemia is a major adverse event associated with insulin secretagogues. Previous studies have suggested a potential relationship between angiotensin-converting enzyme inhibitors (ACEIs) used with sulfonylureas and serious hypoglycemia, and widely used drug compendia warn of this potential drug-drug...

Cite
Hee Nam Y, Brensinger CM, Bilker WB, et al. Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia. Clin Pharmacol Ther. 2021;doi: 10.1002/cpt.2377.
Hee Nam, Y., Brensinger, C. M., Bilker, W. B., Flory, J. H., Leonard, C. E., & Hennessy, S. (2021). Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia. Clinical pharmacology and therapeutics, . https://doi.org/10.1002/cpt.2377
Hee Nam, Young, et al. "Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia." Clinical pharmacology and therapeutics vol. (2021). doi: https://doi.org/10.1002/cpt.2377
Hee Nam Y, Brensinger CM, Bilker WB, Flory JH, Leonard CE, Hennessy S. Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia. Clin Pharmacol Ther. 2021 Jul 27; doi: 10.1002/cpt.2377. Epub 2021 Jul 27. PMID: 34312836.
Copy Download .nbib Format: NLM
Use of oral anti-diabetic agents in pregnancy: a pragmatic approach.

North American journal of medical sciences

Kalra B, Gupta Y, Singla R, Kalra S.
PMID: 25709972
N Am J Med Sci. 2015 Jan;7(1):6-12. doi: 10.4103/1947-2714.150081.

Insulin is the gold standard for treatment of hyperglycemia during pregnancy, when lifestyle measures do not maintain glycemic control during pregnancy. However, recent studies have suggested that certain oral hypoglycemic agents (metformin and glyburide) may be safe and be...

Cite
Kalra B, Gupta Y, Singla R, et al. Use of oral anti-diabetic agents in pregnancy: a pragmatic approach. N Am J Med Sci. 2015;7(1):6-12doi: 10.4103/1947-2714.150081.
Kalra, B., Gupta, Y., Singla, R., & Kalra, S. (2015). Use of oral anti-diabetic agents in pregnancy: a pragmatic approach. North American journal of medical sciences, 7(1), 6-12. https://doi.org/10.4103/1947-2714.150081
Kalra, Bharti, et al. "Use of oral anti-diabetic agents in pregnancy: a pragmatic approach." North American journal of medical sciences vol. 7,1 (2015): 6-12. doi: https://doi.org/10.4103/1947-2714.150081
Kalra B, Gupta Y, Singla R, Kalra S. Use of oral anti-diabetic agents in pregnancy: a pragmatic approach. N Am J Med Sci. 2015 Jan;7(1):6-12. doi: 10.4103/1947-2714.150081. PMID: 25709972; PMCID: PMC4325398.
Copy Download .nbib Format: NLM
Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia.

Clinical pharmacology and therapeutics

Hee Nam Y, Brensinger CM, Bilker WB, Flory JH, Leonard CE, Hennessy S.
PMID: 34312836
Clin Pharmacol Ther. 2022 Jan;111(1):218-226. doi: 10.1002/cpt.2377. Epub 2021 Aug 23.

Serious hypoglycemia is a major adverse event associated with insulin secretagogues. Previous studies have suggested a potential relationship between angiotensin-converting enzyme inhibitors (ACEIs) used with sulfonylureas and serious hypoglycemia, and widely used drug compendia warn of this potential drug-drug...

Cite
Hee Nam Y, Brensinger CM, Bilker WB, et al. Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia. Clin Pharmacol Ther. 2021;111(1):218-226doi: 10.1002/cpt.2377.
Hee Nam, Y., Brensinger, C. M., Bilker, W. B., Flory, J. H., Leonard, C. E., & Hennessy, S. (2022). Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia. Clinical pharmacology and therapeutics, 111(1), 218-226. https://doi.org/10.1002/cpt.2377
Hee Nam, Young, et al. "Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia." Clinical pharmacology and therapeutics vol. 111,1 (2022): 218-226. doi: https://doi.org/10.1002/cpt.2377
Hee Nam Y, Brensinger CM, Bilker WB, Flory JH, Leonard CE, Hennessy S. Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia. Clin Pharmacol Ther. 2022 Jan;111(1):218-226. doi: 10.1002/cpt.2377. Epub 2021 Aug 23. PMID: 34312836.
Copy Download .nbib Format: NLM
Refocusing on public policy--in step with member value.

Journal of the American Dietetic Association

Glibride J, Samour P, Hill L, Pavlinac J.
PMID: 12487535
J Am Diet Assoc. 2002 Dec;102(12):1752-3. doi: 10.1016/s0002-8223(02)90376-7.

No abstract available.

Cite
Glibride J, Samour P, Hill L, et al. Refocusing on public policy--in step with member value. J Am Diet Assoc. 2002;102(12):1752-3doi: 10.1016/s0002-8223(02)90376-7.
Glibride, J., Samour, P., Hill, L., & Pavlinac, J. (2002). Refocusing on public policy--in step with member value. Journal of the American Dietetic Association, 102(12), 1752-3. https://doi.org/10.1016/s0002-8223(02)90376-7
Glibride, Judith, et al. "Refocusing on public policy--in step with member value." Journal of the American Dietetic Association vol. 102,12 (2002): 1752-3. doi: https://doi.org/10.1016/s0002-8223(02)90376-7
Glibride J, Samour P, Hill L, Pavlinac J. Refocusing on public policy--in step with member value. J Am Diet Assoc. 2002 Dec;102(12):1752-3. doi: 10.1016/s0002-8223(02)90376-7. PMID: 12487535.
Copy Download .nbib Format: NLM
Pinacidil's Effects on Defibrillation Outcomes: Role of Increased Potassium Conductance Via the K(ATP) Channel.

Journal of cardiovascular pharmacology and therapeutics

Winecoff AP, Sims JJ, Markel ML, Ujhelyi MR.
PMID: 10684456
J Cardiovasc Pharmacol Ther. 1997 Jul;2(3):171-180. doi: 10.1177/107424849700200304.

BACKGROUND: It has been shown that the inhibition of potassium ion conductance decreases defibrillation threshold. We postulated that if potassium conductance is a primary mechanism affecting defibrillation threshold values, then increasing potassium ion conductance will increase defibrillation values. The...

Cite
Winecoff AP, Sims JJ, Markel ML, et al. Pinacidil's Effects on Defibrillation Outcomes: Role of Increased Potassium Conductance Via the K(ATP) Channel. J Cardiovasc Pharmacol Ther. 1997;2(3):171-180doi: 10.1177/107424849700200304.
Winecoff, A. P., Sims, J. J., Markel, M. L., & Ujhelyi, M. R. (1997). Pinacidil's Effects on Defibrillation Outcomes: Role of Increased Potassium Conductance Via the K(ATP) Channel. Journal of cardiovascular pharmacology and therapeutics, 2(3), 171-180. https://doi.org/10.1177/107424849700200304
Winecoff, et al. "Pinacidil's Effects on Defibrillation Outcomes: Role of Increased Potassium Conductance Via the K(ATP) Channel." Journal of cardiovascular pharmacology and therapeutics vol. 2,3 (1997): 171-180. doi: https://doi.org/10.1177/107424849700200304
Winecoff AP, Sims JJ, Markel ML, Ujhelyi MR. Pinacidil's Effects on Defibrillation Outcomes: Role of Increased Potassium Conductance Via the K(ATP) Channel. J Cardiovasc Pharmacol Ther. 1997 Jul;2(3):171-180. doi: 10.1177/107424849700200304. PMID: 10684456.
Copy Download .nbib Format: NLM
Clinical trials with glimepiride.

Drugs of today (Barcelona, Spain : 1998)

Clark CM, Helmy AW.
PMID: 15010703
Drugs Today (Barc). 1998 May;34(5):401-8. doi: 10.1358/dot.1998.34.5.472186.

Data from 21 placebo-controlled, active-controlled or noncomparative studies involving more than 6500 patients, more than 4220 of whom were treated with glimepiride, are reviewed. Glimepiride has a rapid onset of action and is effective at a single daily dose....

Cite
Clark CM, Helmy AW. Clinical trials with glimepiride. Drugs Today (Barc). 1998;34(5):401-8doi: 10.1358/dot.1998.34.5.472186.
Clark, C. M., & Helmy, A. W. (1998). Clinical trials with glimepiride. Drugs of today (Barcelona, Spain : 1998), 34(5), 401-8. https://doi.org/10.1358/dot.1998.34.5.472186
Clark, C M, and Helmy, A W. "Clinical trials with glimepiride." Drugs of today (Barcelona, Spain : 1998) vol. 34,5 (1998): 401-8. doi: https://doi.org/10.1358/dot.1998.34.5.472186
Clark CM, Helmy AW. Clinical trials with glimepiride. Drugs Today (Barc). 1998 May;34(5):401-8. doi: 10.1358/dot.1998.34.5.472186. PMID: 15010703.
Copy Download .nbib Format: NLM
Role of Various Potassium Channels in Caffeine-induced Aortic Relaxation in Rats.

Saudi journal of medicine & medical sciences

Latif R, Badar A.
PMID: 30787729
Saudi J Med Med Sci. 2016 Sep-Dec;4(3):197-201. doi: 10.4103/1658-631X.188251. Epub 2016 Aug 11.

BACKGROUND: Studies done on caffeine-induced changes in aortic rings have demonstrated inconclusive results. Moreover, the role of various potassium channels in caffeine-induced effects has not been explored so far. The present MATERIALS AND METHODS: This study was carried out...

Cite
Latif R, Badar A. Role of Various Potassium Channels in Caffeine-induced Aortic Relaxation in Rats. Saudi J Med Med Sci. 2016;4(3):197-201doi: 10.4103/1658-631X.188251.
Latif, R., & Badar, A. (2016). Role of Various Potassium Channels in Caffeine-induced Aortic Relaxation in Rats. Saudi journal of medicine & medical sciences, 4(3), 197-201. https://doi.org/10.4103/1658-631X.188251
Latif, Rabia, and Badar, Ahmed. "Role of Various Potassium Channels in Caffeine-induced Aortic Relaxation in Rats." Saudi journal of medicine & medical sciences vol. 4,3 (2016): 197-201. doi: https://doi.org/10.4103/1658-631X.188251
Latif R, Badar A. Role of Various Potassium Channels in Caffeine-induced Aortic Relaxation in Rats. Saudi J Med Med Sci. 2016 Sep-Dec;4(3):197-201. doi: 10.4103/1658-631X.188251. Epub 2016 Aug 11. PMID: 30787729; PMCID: PMC6298334.
Copy Download .nbib Format: NLM
Increased fracture risk in patients treated with thiazolidinediones: the role of abnormal bone turnover.

Expert review of endocrinology & metabolism

Cooper M.
PMID: 30764043
Expert Rev Endocrinol Metab. 2010 Mar;5(2):177-180. doi: 10.1586/eem.10.4.

Evaluation of: Zinman B, Haffner SM, Herman WH et al. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab. 95(1), 134-142 (2010). Until recently, patients with Type 2 diabetes...

Cite
Cooper M. Increased fracture risk in patients treated with thiazolidinediones: the role of abnormal bone turnover. Expert Rev Endocrinol Metab. 2010;5(2):177-180doi: 10.1586/eem.10.4.
Cooper, M. (2010). Increased fracture risk in patients treated with thiazolidinediones: the role of abnormal bone turnover. Expert review of endocrinology & metabolism, 5(2), 177-180. https://doi.org/10.1586/eem.10.4
Cooper, Mark. "Increased fracture risk in patients treated with thiazolidinediones: the role of abnormal bone turnover." Expert review of endocrinology & metabolism vol. 5,2 (2010): 177-180. doi: https://doi.org/10.1586/eem.10.4
Cooper M. Increased fracture risk in patients treated with thiazolidinediones: the role of abnormal bone turnover. Expert Rev Endocrinol Metab. 2010 Mar;5(2):177-180. doi: 10.1586/eem.10.4. PMID: 30764043.
Copy Download .nbib Format: NLM
Improved glycemic control with use of oral hypoglycemic therapy with or without insulin.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Bell DS, Mayo MS.
PMID: 15251750
Endocr Pract. 1998 Mar-Apr;4(2):82-5. doi: 10.4158/EP.4.2.82.

OBJECTIVE: To determine whether combination oral hypoglycemic therapy in insulin-using patients with non-insulin-dependent diabetes mellitus (NIDDM) can improve glycemic control for a prolonged period.METHODS: We expanded and extended an earlier study to include 130 patients with NIDDM for 10...

Cite
Bell DS, Mayo MS. Improved glycemic control with use of oral hypoglycemic therapy with or without insulin. Endocr Pract. 1998;4(2):82-5doi: 10.4158/EP.4.2.82.
Bell, D. S., & Mayo, M. S. (1998). Improved glycemic control with use of oral hypoglycemic therapy with or without insulin. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 4(2), 82-5. https://doi.org/10.4158/EP.4.2.82
Bell, D S, and Mayo, M S. "Improved glycemic control with use of oral hypoglycemic therapy with or without insulin." Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists vol. 4,2 (1998): 82-5. doi: https://doi.org/10.4158/EP.4.2.82
Bell DS, Mayo MS. Improved glycemic control with use of oral hypoglycemic therapy with or without insulin. Endocr Pract. 1998 Mar-Apr;4(2):82-5. doi: 10.4158/EP.4.2.82. PMID: 15251750.
Copy Download .nbib Format: NLM
Spontaneous hypoglycemia associated with congestive heart failure attributable to hyperinsulinism.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Khoury H, Daugherty T, Ehsanipoor K.
PMID: 15251753
Endocr Pract. 1998 Mar-Apr;4(2):94-5. doi: 10.4158/EP.4.2.94.

OBJECTIVE: To report a case of spontaneous hypoglycemia associated with congestive heart failure in an adult.METHODS: We describe a 72-year-old man in whom profound hypoglycemia (serum glucose level, 21 mg/dL) developed during an exacerbation of heart failure. Clinical and...

Cite
Khoury H, Daugherty T, Ehsanipoor K. Spontaneous hypoglycemia associated with congestive heart failure attributable to hyperinsulinism. Endocr Pract. 1998;4(2):94-5doi: 10.4158/EP.4.2.94.
Khoury, H., Daugherty, T., & Ehsanipoor, K. (1998). Spontaneous hypoglycemia associated with congestive heart failure attributable to hyperinsulinism. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 4(2), 94-5. https://doi.org/10.4158/EP.4.2.94
Khoury, H, et al. "Spontaneous hypoglycemia associated with congestive heart failure attributable to hyperinsulinism." Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists vol. 4,2 (1998): 94-5. doi: https://doi.org/10.4158/EP.4.2.94
Khoury H, Daugherty T, Ehsanipoor K. Spontaneous hypoglycemia associated with congestive heart failure attributable to hyperinsulinism. Endocr Pract. 1998 Mar-Apr;4(2):94-5. doi: 10.4158/EP.4.2.94. PMID: 15251753.
Copy Download .nbib Format: NLM
New therapeutic approaches to non-insulin-dependent diabetes mellitus.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Bloomgarden ZT.
PMID: 15251787
Endocr Pract. 1997 Sep-Oct;3(5):307-12. doi: 10.4158/EP.3.5.307.

OBJECTIVE: To review the new treatment strategies for non-insulin-dependent diabetes mellitus (NIDDM).METHODS: Various measures aimed at either increasing insulin secretion or decreasing insulin resistance are outlined. In addition, the management of obesity in patients with diabetes is discussed.RESULTS: Two...

Cite
Bloomgarden ZT. New therapeutic approaches to non-insulin-dependent diabetes mellitus. Endocr Pract. 1997;3(5):307-12doi: 10.4158/EP.3.5.307.
Bloomgarden, Z. T. (1997). New therapeutic approaches to non-insulin-dependent diabetes mellitus. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 3(5), 307-12. https://doi.org/10.4158/EP.3.5.307
Bloomgarden, Z T. "New therapeutic approaches to non-insulin-dependent diabetes mellitus." Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists vol. 3,5 (1997): 307-12. doi: https://doi.org/10.4158/EP.3.5.307
Bloomgarden ZT. New therapeutic approaches to non-insulin-dependent diabetes mellitus. Endocr Pract. 1997 Sep-Oct;3(5):307-12. doi: 10.4158/EP.3.5.307. PMID: 15251787.
Copy Download .nbib Format: NLM
Alogliptin: a new addition to the class of DPP-4 inhibitors.

Diabetes, metabolic syndrome and obesity : targets and therapy

Andukuri R, Drincic A, Rendell M.
PMID: 21437125
Diabetes Metab Syndr Obes. 2009 Jul 21;2:117-26.

BACKGROUND: Alogliptin is an oral antihyperglycemic agent that is a selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). Inhibition of DPP-4 elevates levels of the incretin hormones glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) by preventing their degradation.OBJECTIVE:...

Cite
Andukuri R, Drincic A, Rendell M. Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabetes Metab Syndr Obes. 2009;2:117-26
Andukuri, R., Drincic, A., & Rendell, M. (2009). Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabetes, metabolic syndrome and obesity : targets and therapy, 2117-26.
Andukuri, Radha, et al. "Alogliptin: a new addition to the class of DPP-4 inhibitors." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 2 (2009): 117-26.
Andukuri R, Drincic A, Rendell M. Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabetes Metab Syndr Obes. 2009 Jul 21;2:117-26. PMID: 21437125; PMCID: PMC3048010.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 122 entries